{"bill": {"@bill-stage": "Introduced-in-Senate", "@public-private": "public", "legis-body": {"#tail": "\n", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "#text": "Preserve Access to Affordable Generics\n\t\t\t Act"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the\n\t\t\t ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "id86EDC939866A4BB6A73AF0BDA5BD2C43"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n\t\t\t", "#text": "Congressional\n\t\t\t findings and declaration of purposes"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "Congress\n\t\t\t finds the following:"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Findings"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "quote": {"#tail": "), was enacted with the intent of\n\t\t\t facilitating the early entry of generic drugs while preserving incentives for\n\t\t\t innovation.", "#text": "1984 Act"}, "#text": "In 1984, the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " (referred\n\t\t\t to in this Act as the ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Drug\n\t\t\t Price Competition and Patent Term Restoration Act", "@value": "Drug Price Competition and Patent Term Restoration Act"}, {"#tail": ")", "@entity-type": "public-law", "#text": "Public Law 98\u2013417", "@value": "public-law/98/417"}], "@entity-type": "law-citation", "#text": "\n              "}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "idD1DDDFFF0CF74BADA11CF9634DB54D68", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "Prescription\n\t\t\t drugs make up 10 percent of the national health care spending but for the past\n\t\t\t decade have been one of the fastest growing segments of health care\n\t\t\t expenditures."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "idFC5C9DD3119D49FFB1916854D168B496", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "Until recently,\n\t\t\t the 1984 Act was successful in facilitating generic competition to the benefit\n\t\t\t of consumers and health care payers\u2014although 67 percent of all prescriptions\n\t\t\t dispensed in the United States are generic drugs, they account for only 20\n\t\t\t percent of all expenditures."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "idDE13742929BD4A8E973F8CD82719B413", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "Generic drugs\n\t\t\t cost substantially less than brand name drugs, with discounts off the brand\n\t\t\t price sometimes exceeding 90 percent."}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "idCB147BAB973E4496B7A6B1D3FAC1E42F", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "Federal dollars\n\t\t\t currently account for an estimated 35 percent of the $263,000,000,000 spent on\n\t\t\t prescription drugs, and this share is expected to rise to 42 percent by\n\t\t\t 2021."}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "@id": "idBCC57BA09EDA42A5B6C59A3A79141082", "#text": "\n          "}, {"#tail": "\n      ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "quote": {"#tail": " which are payments by the brand company to the\n\t\t\t generic company.", "#text": "reverse payments"}, "#text": "In recent years, the\n\t\t\t intent of the 1984 Act has been subverted by certain settlement agreements\n\t\t\t between brand companies and their potential generic competitors that make\n\t\t\t "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@display-inline": "yes-display-inline", "#text": "\n            ", "@id": "id452D755DAB764402BCB2A908EEA35DD9", "@commented": "no"}, {"@indent": "up1", "#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "These settlement agreements have\n\t\t\t unduly delayed the marketing of low-cost generic drugs contrary to free\n\t\t\t competition, the interests of consumers, and the principles underlying\n\t\t\t antitrust law."}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "#text": "\n            ", "@id": "idCB09AA1594544BB29E1DC1576C3306EF"}, {"@indent": "up1", "#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "Because of the price disparity between\n\t\t\t brand name and generic drugs, such agreements are more profitable for both the\n\t\t\t brand and generic manufacturers than competition, and will become increasingly\n\t\t\t common unless prohibited."}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "#text": "\n            ", "@id": "id13A8CB6F77D042259E34FD22EB4C692F"}, {"@indent": "up1", "#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "These agreements result in consumers\n\t\t\t losing the benefits that the 1984 Act was intended to provide."}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "#text": "\n            ", "@id": "id7FCBE969BB824E40BE3777DBD6DF0E4D"}], "enum": {"#tail": "\n          ", "#text": "(6)"}, "@id": "idEDEA23237CD74F3F946AF0EE3CF645A4", "#text": "\n          "}], "#text": "\n        ", "@id": "id359904593A414EED94638B9697056156"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "#text": "The\n\t\t\t purposes of this Act are\u2014"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Purposes"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "to enhance\n\t\t\t competition in the pharmaceutical market by stopping anticompetitive agreements\n\t\t\t between brand name and generic drug manufacturers that limit, delay, or\n\t\t\t otherwise prevent competition from generic drugs; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "id1B96D00562854784B1B3C9D760EEF96A", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "to support the\n\t\t\t purpose and intent of antitrust law by prohibiting anticompetitive practices in\n\t\t\t the pharmaceutical industry that harm consumers."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "id43318893879C4C7DA353C9739942D377", "#text": "\n          "}], "#text": "\n        ", "@id": "id747DD43FFF9B4A30966D1F063E7A3529"}], "#text": "\n      ", "@id": "id63E9BBDDC1E5451AA88A29CF8F9976F1"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "The\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Federal Trade Commission Act", "@value": "Federal Trade Commission Act"}, {"#tail": ")", "@entity-type": "uscode", "#text": "15 U.S.C. 44 et seq.", "@value": "usc/15/44/etseq"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Unlawful\n\t\t\t compensation for delay"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " as ", "@entity-type": "act", "#text": "section 28", "@value": "Federal Trade Commission Act/s:28"}, {"#tail": "; and", "@entity-type": "act", "#text": "section 29", "@value": "Federal Trade Commission Act/s:29", "@proposed": "true"}], "#text": "redesignating\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "idD815DD162AA946C6B96988D670FE76F1", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", as redesignated, the following:", "@entity-type": "act", "#text": "section 29", "@value": "Federal Trade Commission Act/s:29", "@proposed": "true"}, "#text": "inserting before\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "section": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "28."}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Preserving\n\t\t\t\taccess to affordable generics"}, "subsection": [{"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(a)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "In\n\t\t\t\tgeneral"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may initiate a proceeding\n\t\t\t\tto enforce the provisions of this section against the parties to any agreement\n\t\t\t\tresolving or settling, on a final or interim basis, a patent infringement\n\t\t\t\tclaim, in connection with the sale of a drug product.", "@entity-type": "federal-body", "#text": "Federal Trade Commission", "@entity-id": "2900"}, "#text": "The "}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Enforcement\n\t\t\t\tproceeding"}, "#text": "\n                ", "@id": "id63436B153AD14846B1A8D4E41A2D5F97"}, {"#tail": "\n            ", "subparagraph": [{"#tail": "\n                ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "an ANDA filer\n\t\t\t\treceives anything of value; and"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "idA9199D1F5ED24DB5A8C8A3E5671171F8", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the ANDA filer\n\t\t\t\tagrees to limit or forego research, development, manufacturing, marketing, or\n\t\t\t\tsales of the ANDA product for any period of time."}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "id15D0A68806C2453388D43A66E42DABC3", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", in such a proceeding, an\n\t\t\t\tagreement shall be presumed to have anticompetitive effects and be unlawful\n\t\t\t\tif\u2014", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "Federal Trade Commission Act/s:28/ss:a/p:1/sp:A", "@proposed": "true"}, "#text": "Subject to "}, "#text": "\n                  ", "@id": "id32221487CDDA4860A29E6C9D880C612F"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall not apply if the parties to such\n\t\t\t\tagreement demonstrate by clear and convincing evidence that the procompetitive\n\t\t\t\tbenefits of the agreement outweigh the anticompetitive effects of the\n\t\t\t\tagreement.", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Trade Commission Act/s:28/ss:a/p:1/sp:A", "@proposed": "true"}, "#text": "The\n\t\t\t\tpresumption in "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Exception"}, "#text": "\n                  ", "@id": "idBA44F11F30B8483FAA75E3BA17E1B2D0"}], "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Presumption"}, "#text": "\n                ", "@id": "id1E285B8FCB804B2C9C643CC1F571F63D"}], "#text": "\n              ", "@id": "id1667386B3E624AC68C63EA2C6A7371C5"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the fact finder shall consider\u2014", "@entity-type": "act", "#text": "subsection (a)(2)(B)", "@value": "Federal Trade Commission Act/s:28/ss:a/p:2/sp:B", "@proposed": "true"}, "#text": "In determining whether the settling parties have met\n\t\t\t\ttheir burden under "}, "enum": {"#tail": "\n              ", "#text": "(b)"}, "header": {"#tail": "\n              ", "#text": "Competitive\n\t\t\t\tfactors"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the length of\n\t\t\t\ttime remaining until the end of the life of the relevant patent, compared with\n\t\t\t\tthe agreed upon entry date for the ANDA product;"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "@id": "id94CA010F8DA3402A9BD487B35308C129", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the value to\n\t\t\t\tconsumers of the competition from the ANDA product allowed under the\n\t\t\t\tagreement;"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "@id": "id5B11B8CE6B504CDC8788750A556FCD90", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the form and\n\t\t\t\tamount of consideration received by the ANDA filer in the agreement resolving\n\t\t\t\tor settling the patent infringement claim;"}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "@id": "id2719A0FAEB46469893444FF970011CFF", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the revenue the\n\t\t\t\tANDA filer would have received by winning the patent litigation;"}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "@id": "id290EEBAAC98C4B7AA3761C0A57E6275C", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the reduction in\n\t\t\t\tthe NDA holder's revenues if it had lost the patent litigation;"}, "enum": {"#tail": "\n                ", "#text": "(5)"}, "@id": "id79FB09A3CE9F40649F4AD3515A89A5CA", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the time period\n\t\t\t\tbetween the date of the agreement conveying value to the ANDA filer and the\n\t\t\t\tdate of the settlement of the patent infringement claim; and"}, "enum": {"#tail": "\n                ", "#text": "(6)"}, "@id": "id307204363EAD4BD6AAAC869C76298FBB", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "any other factor\n\t\t\t\tthat the fact finder, in its discretion, deems relevant to its determination of\n\t\t\t\tcompetitive effects under this subsection."}, "enum": {"#tail": "\n                ", "#text": "(7)"}, "@id": "idB5F40BB671E44170B91FF1A4489AE971", "#text": "\n                "}], "#text": "\n              ", "@id": "id615D4D72DF82411882E92CDAC50B6A85"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the fact finder shall not presume\u2014", "@entity-type": "act", "#text": "subsection\n\t\t\t\t(a)(2)(B)", "@value": "Federal Trade Commission Act/s:28/ss:a/p:2/sp:B", "@proposed": "true"}, "#text": "In\n\t\t\t\tdetermining whether the settling parties have met their burden under "}, "enum": {"#tail": "\n              ", "#text": "(c)"}, "header": {"#tail": "\n              ", "#text": "Limitations"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "that entry would\n\t\t\t\tnot have occurred until the expiration of the relevant patent or statutory\n\t\t\t\texclusivity; or"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "@id": "id8D14AB9179334CEFBF7A1DAA741CA22D", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "that the\n\t\t\t\tagreement's provision for entry of the ANDA product prior to the expiration of\n\t\t\t\tthe relevant patent or statutory exclusivity means that the agreement is\n\t\t\t\tpro-competitive, although such evidence may be relevant to the fact finder's\n\t\t\t\tdetermination under this section."}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "@id": "id02A1905E17D24165A5CBE95F1E257E8E", "#text": "\n                "}], "#text": "\n              ", "@id": "id2BA71E1AF5C54D7288E5650FA4E5A8F1"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Nothing\n\t\t\t\tin this section shall prohibit a resolution or settlement of a patent\n\t\t\t\tinfringement claim in which the consideration granted by the NDA holder to the\n\t\t\t\tANDA filer as part of the resolution or settlement includes only one or more of\n\t\t\t\tthe following:"}, "enum": {"#tail": "\n              ", "#text": "(d)"}, "header": {"#tail": "\n              ", "#text": "Exclusions"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The right to\n\t\t\t\tmarket the ANDA product in the United States prior to the expiration of\u2014"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "#text": "\n                ", "@id": "idC4233AE997424716A592E8D86F1D51E9", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "any patent that\n\t\t\t\tis the basis for the patent infringement claim; or"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "id253FF1F071564DA7B90DF26DDE6F0490", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "any patent right\n\t\t\t\tor other statutory exclusivity that would prevent the marketing of such\n\t\t\t\tdrug."}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "idAD30D6A58D7E4AE9969C528B0D5A72F8", "#text": "\n                  "}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "A payment for\n\t\t\t\treasonable litigation expenses not to exceed $7,500,000."}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "@id": "id69F79E95896549DA8CCD9C08EB155F2E", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "A covenant not to\n\t\t\t\tsue on any claim that the ANDA product infringes a United States patent."}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "@id": "idB328783C939A4DA18FB13E29F4BF3174", "#text": "\n                "}], "#text": "\n              ", "@id": "idFB8D3387521043A398B7C336A6B02F7F"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(e)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Regulations and\n\t\t\t\tenforcement"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may issue, in accordance with ", "@entity-type": "federal-body", "#text": "Federal Trade Commission", "@entity-id": "2900"}, {"#tail": ", regulations implementing and interpreting this section.\n\t\t\t\tThese regulations may exempt certain types of agreements described in\n\t\t\t\t", "@entity-type": "uscode", "#text": "section 553 of title 5,\n\t\t\t\tUnited States Code", "@value": "usc/5/553"}, {"#tail": " if the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Trade Commission Act/s:28/ss:a"}, {"#tail": " determines such agreements will further market\n\t\t\t\tcompetition and benefit consumers. Judicial review of any such regulation shall\n\t\t\t\tbe in the United States District Court for the District of Columbia pursuant to\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, {"#tail": ".", "@entity-type": "uscode", "#text": "section 706 of title 5, United States Code", "@value": "usc/5/706"}], "#text": "The\n\t\t\t\t"}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Regulations"}, "#text": "\n                ", "@id": "IDfbba9370d2eb407fa527883dda5105a3"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "A\n\t\t\t\tviolation of this section shall be treated as a violation of section 5."}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Enforcement"}, "#text": "\n                ", "@id": "ID1a51445221234918b7dabd4e3f4d5813"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", issued in an administrative adjudicative\n\t\t\t\tproceeding under the authority of ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, {"#tail": ", may, within 30 days of the\n\t\t\t\tissuance of such order, petition for review of such order in the United States\n\t\t\t\tCourt of Appeals for the District of Columbia Circuit or the United States\n\t\t\t\tCourt of Appeals for the circuit in which the ultimate parent entity, as\n\t\t\t\tdefined at 16 CFR 801.1(a)(3), of the NDA holder is incorporated as of the date\n\t\t\t\tthat the NDA is filed with the ", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "Federal Trade Commission Act/s:28/ss:a/p:1", "@proposed": "true"}, {"#tail": ",\n\t\t\t\tor the United States Court of Appeals for the circuit in which the ultimate\n\t\t\t\tparent entity of the ANDA filer is incorporated as of the date that the ANDA is\n\t\t\t\tfiled with the ", "@entity-type": "federal-body", "#text": "Secretary of the Food and Drug Administration", "@entity-id": "7524"}, {"#tail": ". In such a review\n\t\t\t\tproceeding, the findings of the ", "@entity-type": "federal-body", "#text": "Secretary of the Food and Drug Administration", "@entity-id": "7524"}, {"#tail": " as to the facts, if supported by\n\t\t\t\tevidence, shall be conclusive.", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}], "#text": "Any person, partnership or corporation that is subject to\n\t\t\t\ta final order of the "}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Judicial\n\t\t\t\treview"}, "#text": "\n                ", "@id": "IDc6285493752f49bca374fc1db32af1f4"}], "#text": "\n              ", "@id": "ID9cb476ba491047adafcba4fc19ac64ef"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to the extent that section 5 applies to unfair methods of competition.\n\t\t\t\tNothing in this section shall modify, impair, limit or supersede the right of\n\t\t\t\tan ANDA filer to assert claims or counterclaims against any person, under the\n\t\t\t\tantitrust laws or other laws relating to unfair competition.", "@entity-type": "act", "#text": "section 5 of\n\t\t\t\tthis Act", "@value": "Clayton Act/s:5"}, "#text": "Nothing in this section shall be construed to modify, impair\n\t\t\t\tor supersede the applicability of the antitrust laws as defined in ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " and of ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "subsection\n\t\t\t\t(a) of the 1st section of the Clayton Act", "@value": "Clayton Act/s:1/ss:a"}, {"#tail": ")", "@entity-type": "uscode", "#text": "15 U.S.C. 12(a)", "@value": "usc/15/12/a"}], "@entity-type": "law-citation", "#text": "\n                  "}}, "enum": {"#tail": "\n              ", "#text": "(f)"}, "header": {"#tail": "\n              ", "#text": "Antitrust\n\t\t\t\tlaws"}, "#text": "\n              ", "@id": "IDa94a161bea14469e9672f06f1a17598a"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(g)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Penalties"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", in its own name by any of its attorneys\n\t\t\t\tdesignated by it for such purpose, in a district court of the United States\n\t\t\t\tagainst any person, partnership or corporation that violates this section. In\n\t\t\t\tsuch actions, the United States district courts are empowered to grant\n\t\t\t\tmandatory injunctions and such other and further equitable relief as they deem\n\t\t\t\tappropriate.", "@entity-type": "federal-body", "#text": "Federal Trade Commission", "@entity-id": "2900"}, "#text": "Each\n\t\t\t\tperson, partnership or corporation that violates or assists in the violation of\n\t\t\t\tthis section shall forfeit and pay to the United States a civil penalty\n\t\t\t\tsufficient to deter violations of this section, but in no event greater than 3\n\t\t\t\ttimes the value received by the party that is reasonably attributable to a\n\t\t\t\tviolation of this section. If no such value has been received by the NDA\n\t\t\t\tholder, the penalty to the NDA holder shall be sufficient to deter violations,\n\t\t\t\tbut in no event greater than 3 times the value given to the ANDA filer\n\t\t\t\treasonably attributable to the violation of this section. Such penalty shall\n\t\t\t\taccrue to the United States and may be recovered in a civil action brought by\n\t\t\t\tthe "}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Forfeiture"}, "#text": "\n                ", "@id": "ID48d126dde11f41bea37b8c26ab42cdb5"}, {"#tail": "\n              ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " has issued a cease and desist order\n\t\t\t\twith respect to a person, partnership or corporation in an administrative\n\t\t\t\tadjudicative proceeding under the authority of ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, {"#tail": ", an action\n\t\t\t\tbrought pursuant to ", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "Federal Trade Commission Act/s:28/ss:a/p:1", "@proposed": "true"}, {"#tail": " may be commenced against such person,\n\t\t\t\tpartnership or corporation at any time before the expiration of one year after\n\t\t\t\tsuch order becomes final pursuant to ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Trade Commission Act/s:28/ss:a/p:1", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "section 5(g)", "@value": "Federal Trade Commission Act/s:5/ss:g", "@proposed": "true"}], "#text": "If the "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n                  ", "@id": "id1B31F24FB9DA4A61AD42948DA4E763C2"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "'s findings shall\n\t\t\t\tnot be conclusive; or", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, "#text": "the terms of such\n\t\t\t\tcease and desist order expressly provide that the "}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "id57762BD58A6346FCA77EFA50E8299B1A", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", in which case such finding shall be\n\t\t\t\tconclusive if supported by evidence.", "@entity-type": "act", "#text": "section 5(g)(1)", "@value": "Federal Trade Commission Act/s:5/ss:g/p:1"}, "#text": "the order became\n\t\t\t\tfinal by reason of "}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "id0D2FF1ED8312499DA592E112CE4FA146", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Exception"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the findings of the ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Trade Commission Act/s:28/ss:g/p:2/sp:A", "@proposed": "true"}, {"#tail": " as to the\n\t\t\t\tmaterial facts in the administrative adjudicative proceeding with respect to\n\t\t\t\tsuch person's, partnership's or corporation's violation of this section shall\n\t\t\t\tbe conclusive unless\u2014", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}], "#text": "In\n\t\t\t\tan action under "}, "#text": "\n                  ", "@id": "idF6D9A2CD95EC4CE79D6DA73604A5C991"}], "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Cease and\n\t\t\t\tdesist"}, "#text": "\n                ", "@id": "ID79513dc7ef114b7c9cc8b0b2fc9f91f8"}, {"#tail": "\n              ", "@id": "ID5c8b854069124cce8fccb7a8d348cd07", "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "Civil\n\t\t\t\tpenalty"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "In determining the amount of the civil penalty described\n\t\t\t\tin this section, the court shall take into account\u2014"}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the nature,\n\t\t\t\tcircumstances, extent, and gravity of the violation;"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "ID5f347dd5c79947ef98685e9a8bf2ac07", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "with respect to\n\t\t\t\tthe violator, the degree of culpability, any history of violations, the ability\n\t\t\t\tto pay, any effect on the ability to continue doing business, profits earned by\n\t\t\t\tthe NDA holder, compensation received by the ANDA filer, and the amount of\n\t\t\t\tcommerce affected; and"}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "IDb0cb627f8e9d48a59d1fabcc7bcbdf47", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "other matters\n\t\t\t\tthat justice requires."}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@id": "ID82310c320dbf44ef8058272ca8d0c78a", "#text": "\n                  "}]}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " under\n\t\t\t\tany other provision of law.", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, "#text": "Remedies provided in this subsection are in addition to,\n\t\t\t\tand not in lieu of, any other remedy provided by Federal law. Nothing in this\n\t\t\t\tparagraph shall be construed to affect any authority of the "}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "Remedies in\n\t\t\t\taddition"}, "#text": "\n                ", "@id": "ID0d6514da899b4b4e8b7179eb05089c8a"}], "#text": "\n              ", "@id": "ID283df0e6ecb14258818f3cddcd948d31"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "In this section:", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(h)"}, "header": {"#tail": "\n              ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 5 of this\n\t\t\t\tAct", "@value": "Sherman Act/s:5"}, "term": {"#tail": " means anything that would constitute an agreement\n\t\t\t\tunder ", "#text": "agreement"}, "#text": "The\n\t\t\t\tterm ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " or ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 1 of the Sherman Act", "@value": "Sherman Act/s:1"}, {"#tail": ")", "@entity-type": "uscode", "#text": "15 U.S.C. 1", "@value": "usc/15/1"}], "@entity-type": "law-citation", "#text": "\n                    "}}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "Agreement"}, "#text": "\n                ", "@id": "ID9a0af5253299480195f32b9ee9648c98"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": "\n\t\t\t\tincludes any agreement that is entered into within 30 days of the resolution or\n\t\t\t\tthe settlement of the claim, or any other agreement that is contingent upon,\n\t\t\t\tprovides a contingent condition for, or is otherwise related to the resolution\n\t\t\t\tor settlement of the claim.", "#text": "agreement resolving or settling a patent infringement claim"}, "#text": "The term\n\t\t\t\t"}, "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Agreement\n\t\t\t\tresolving or settling a patent infringement claim"}, "#text": "\n                ", "@id": "ID6ea793b8002a4f0285f5a7055c9bd226"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means an abbreviated new drug application, as defined\n\t\t\t\tunder ", "#text": "ANDA"}, "#text": "The\n\t\t\t\tterm ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 505(j) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C.\n\t\t\t\t355(j)", "@value": "usc/21/355/j"}], "@entity-type": "law-citation", "#text": "\n                    "}}, "enum": {"#tail": "\n                ", "#text": "(3)"}, "header": {"#tail": "\n                ", "#text": "ANDA"}, "#text": "\n                ", "@id": "ID56929fbb211a414ca7df0fbb683234e8"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "term": {"#tail": " means a party who has\n\t\t\t\tfiled an ANDA with the ", "#text": "ANDA filer"}, "#text": "The term "}, "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n                ", "#text": "ANDA\n\t\t\t\tfiler"}, "#text": "\n                ", "@id": "IDc0463528122544fca03f40f990882fa8"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means the product to\n\t\t\t\tbe manufactured under the ANDA that is the subject of the patent infringement\n\t\t\t\tclaim.", "#text": "ANDA product"}, "#text": "The term "}, "enum": {"#tail": "\n                ", "#text": "(5)"}, "header": {"#tail": "\n                ", "#text": "ANDA\n\t\t\t\tproduct"}, "#text": "\n                ", "@id": "ID930cab20a44c40a3ba82c94467a12479"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "uscode", "#text": "section 314.3(b) of title 21, Code of Federal\n\t\t\t\tRegulations", "@value": "usc/21,Code/314.3/b"}, "term": {"#tail": " means a finished\n\t\t\t\tdosage form (e.g., tablet, capsule, or solution) that contains a drug\n\t\t\t\tsubstance, generally, but not necessarily, in association with 1 or more other\n\t\t\t\tingredients, as defined in ", "#text": "drug product"}, "#text": "The term "}, "enum": {"#tail": "\n                ", "#text": "(6)"}, "header": {"#tail": "\n                ", "#text": "Drug\n\t\t\t\tproduct"}, "#text": "\n                ", "@id": "ID7ea5e89cb6bc44e8b397166c12d0b3f8"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means a new drug application, as defined under ", "#text": "NDA"}, "#text": "The\n\t\t\t\tterm ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section\n\t\t\t\t505(b) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 355(b)", "@value": "usc/21/355/b"}], "@entity-type": "law-citation", "#text": "\n                    "}}, "enum": {"#tail": "\n                ", "#text": "(7)"}, "header": {"#tail": "\n                ", "#text": "NDA"}, "#text": "\n                ", "@id": "ID4135ca39ff4742d88c6fbee3adc6109f"}, {"#tail": "\n              ", "@id": "ID9b609efd4f314ee09c9b4ab27baa9a1a", "enum": {"#tail": "\n                ", "#text": "(8)"}, "header": {"#tail": "\n                ", "#text": "NDA\n\t\t\t\tholder"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "term": {"#tail": " means\u2014", "#text": "NDA holder"}, "#text": "The term "}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " approval to market a drug product pursuant to an NDA;", "@entity-type": "federal-body", "#text": "FDA", "@entity-id": "7524"}, "#text": "the party that\n\t\t\t\treceived "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "IDa527cad2148b46038644216eeb49c659", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "quote": {"#tail": ") in connection with the NDA; or", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " Orange\n\t\t\t\tBook", "@entity-type": "federal-body", "#text": "FDA", "@entity-id": "7524"}, "#text": "\n                      "}, "#text": "a party owning or\n\t\t\t\tcontrolling enforcement of the patent listed in the Approved Drug Products With\n\t\t\t\tTherapeutic Equivalence Evaluations (commonly known as the "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "ID019e5d65b2dd4351b12f57dcb90f7cdb", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (such control to be presumed by direct or indirect share ownership of\n\t\t\t\t50 percent or greater), as well as the licensees, licensors, successors, and\n\t\t\t\tassigns of each of the entities.", "@entity-type": "act", "#text": "subparagraphs (A)\n\t\t\t\tand (B)", "@value": "Federal Trade Commission Act/s:28/ss:h/p:8/sp:A,B"}, "#text": "the predecessors,\n\t\t\t\tsubsidiaries, divisions, groups, and affiliates controlled by, controlling, or\n\t\t\t\tunder common control with any of the entities described in "}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@id": "ID78bbded87bf24bc38dc348801496b192", "#text": "\n                  "}]}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means\n\t\t\t\tinfringement of any patent or of any filed patent application, extension,\n\t\t\t\treissue, renewal, division, continuation, continuation in part, reexamination,\n\t\t\t\tpatent term restoration, patents of addition and extensions thereof.", "#text": "patent infringement"}, "#text": "The term "}, "enum": {"#tail": "\n                ", "#text": "(9)"}, "header": {"#tail": "\n                ", "#text": "Patent\n\t\t\t\tinfringement"}, "#text": "\n                ", "@id": "ID6dadb22b8d1b487980506fad0963be74"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means any allegation made to an ANDA filer, whether or not\n\t\t\t\tincluded in a complaint filed with a court of law, that its ANDA or ANDA\n\t\t\t\tproduct may infringe any patent held by, or exclusively licensed to, the NDA\n\t\t\t\tholder of the drug product.", "#text": "patent infringement\n\t\t\t\tclaim"}, "#text": "The term "}, "enum": {"#tail": "\n                ", "#text": "(10)"}, "header": {"#tail": "\n                ", "#text": "Patent\n\t\t\t\tinfringement claim"}, "#text": "\n                ", "@id": "IDeff66b69e3b647bf8213e37fd877b00f"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (5- and 3-year data exclusivity), ", "@entity-type": "act", "#text": "clauses (ii)\n\t\t\t\tthrough (iv) of section 505(c)(3)(E)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:ii..iv"}, {"#tail": " (orphan drug exclusivity), or ", "@entity-type": "act", "#text": "section\n\t\t\t\t527", "@value": "Federal Food, Drug, and Cosmetic Act/s:527"}, {"#tail": " (pediatric exclusivity) of the\n\t\t\t\t", "@entity-type": "act", "#text": "section 505A", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, {"#tail": ".", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic\n\t\t\t\tAct", "@value": "Federal Food, Drug, and Cosmetic Act"}], "term": {"#tail": " means\n\t\t\t\tthose prohibitions on the approval of drug applications under ", "#text": "statutory exclusivity"}, "#text": "The term "}, "enum": {"#tail": "\n                ", "#text": "(11)"}, "header": {"#tail": "\n                ", "#text": "Statutory\n\t\t\t\texclusivity"}, "#text": "\n                ", "@id": "idFF88FBD4D5F240ACAE04FB1E92C634E9"}], "#text": "\n              ", "@id": "id45338E1757F643C799B30259F85E0E87"}], "#text": "\n            ", "@id": "id9E27E4CD51C4430B906F95E4CFE64E79"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "id0174E948CF4741B098D1886E9118EE96"}, "#text": "\n        ", "@id": "id2BBD926123F740B4B8C9ADF8127910F9"}], "#text": "\n      ", "@id": "idB4948234563249969FAC1E282B914B90"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n\t\t\t", "#text": "Notice and\n\t\t\t certification of agreements"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\n\t\t\t by\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section 1112(c)(2) of the Medicare Prescription Drug,\n\t\t\t Improvement, and Modernization Act of 2003", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:c/p:2"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 355 note", "@value": "usc/21/355/note"}], "@entity-type": "law-citation", "#text": "\n            "}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Notice of all\n\t\t\t agreements"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "quote": {"#tail": " and inserting the following: \u201cthe\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, "#text": "the "}, "#text": "striking\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": ";"}, "#tail": "\n\t\t\t\t", "paragraph": {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "the"}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "@id": "id8C3EE51A6F424F549A7A6020230FFFAD", "#text": "\n              "}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t", "@id": "id1574443D1642473587596FD6A608FEF2"}, "#text": "\n          ", "@id": "ID1e9e22c7333d4677b7ce883798907320"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "quote": {"#tail": "; and", "#text": "; and"}, "#text": "striking the\n\t\t\t period and inserting "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "idE8C81546832544F9B220CE569383E074", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "inserting at the\n\t\t\t end the following:"}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n\t\t\t\t", "paragraph": {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or\n\t\t\t\t", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a"}, {"#tail": ".", "@entity-type": "act", "#text": "(b)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:b"}], "#text": "any other\n\t\t\t\tagreement the parties enter into within 30 days of entering into an agreement\n\t\t\t\tcovered by "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@id": "id0CBAD188A10E4959B221CE5D73D99A0E", "#text": "\n              "}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t", "@id": "id67D3937098544D308A6DB8A20AB1CF1C"}, "#text": "\n          ", "@id": "ID21dd65a16c3043f9978372346cf0bbb1"}], "#text": "\n        ", "@id": "ID948fbbd1203a4b7fb333ceea27b81e8f"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is amended by adding at\n\t\t\t the end the following:", "@entity-type": "act", "#text": "Section 1112 of such Act", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112"}, "#text": "\n          "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Certification\n\t\t\t of agreements"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "subsection": {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a"}, {"#tail": ", or ", "@entity-type": "act", "#text": "(b)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:b"}, {"#tail": " shall execute\n\t\t\t\tand file with the Assistant Attorney General and the ", "@entity-type": "act", "#text": "(c)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:c"}, {"#tail": " a certification\n\t\t\t\tas follows: ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}], "#text": "The\n\t\t\t\tChief Executive Officer or the company official responsible for negotiating any\n\t\t\t\tagreement required to be filed under ", "quote": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the ", "@entity-type": "federal-body", "#text": "Federal Trade\n\t\t\t\tCommission", "@entity-id": "2900"}, {"#tail": " under ", "@entity-type": "federal-body", "#text": "Department of Justice", "@entity-id": "1500"}, {"#tail": ", with respect to the agreement referenced in this certification: (1)\n\t\t\t\trepresent the complete, final, and exclusive agreement between the parties; (2)\n\t\t\t\tinclude any ancillary agreements that are contingent upon, provide a contingent\n\t\t\t\tcondition for, or are otherwise related to, the referenced agreement; and (3)\n\t\t\t\tinclude written descriptions of any oral agreements, representations,\n\t\t\t\tcommitments, or promises between the parties that are responsive to ", "@entity-type": "act", "#text": "section 1112 of subtitle B of\n\t\t\t\ttitle XI of the Medicare Prescription Drug, Improvement, and Modernization Act\n\t\t\t\tof 2003", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/t:XI/st:B/s:1112"}, {"#tail": " or ", "@entity-type": "act", "#text": "subsection\n\t\t\t\t(a)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:a"}, {"#tail": " and have not been reduced to\n\t\t\t\twriting.", "@entity-type": "act", "#text": "(b) of such section 1112", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112"}], "#text": "I declare that the following is true, correct, and complete\n\t\t\t\tto the best of my knowledge: The materials filed with the "}}, "enum": {"#tail": "\n            ", "#text": "(d)"}, "header": {"#tail": "\n            ", "#text": "Certification"}, "#text": "\n            ", "@id": "ID5428698343d140d8bdf04af8e6282a76"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "id1E8A6CB53CA3499A90558B1A3525681C"}, "#text": "\n        ", "@id": "ID9fa55d3f27934fad9c6978f1fe5500a4"}], "#text": "\n      ", "@id": "id88AA880E01E44214B36E20F8A664D64D"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": [{"#tail": "\n\t\t\t after ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " or", "@entity-type": "act", "#text": "section 28 of the Federal Trade Commission Act", "@value": "Federal Trade Commission Act/s:28"}, "#text": "\n          "}, {"#tail": ".", "#text": "that the agreement has violated"}], "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by\n\t\t\t inserting ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section 505(j)(5)(D)(i)(V) of the Federal\n\t\t\t Food, Drug and Cosmetic Act", "@value": "Federal Food, Drug and Cosmetic Act/s:505/ss:j/p:5/sp:D/cl:i/scl:V"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 355(j)(5)(D)(i)(V)", "@value": "usc/21/355/j/5/D/i/V"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n      ", "#text": "Forfeiture of\n\t\t\t 180-day exclusivity period"}, "#text": "\n      ", "@id": "id40DCD250172743DC859054FD065456A2"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is\n\t\t\t amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section\n\t\t\t 16(a)(2) of the Federal Trade Commission Act", "@value": "Federal Trade Commission Act/s:16/ss:a/p:2"}, {"#tail": ")", "@entity-type": "uscode", "#text": "15 U.S.C. 56(a)(2)", "@value": "usc/15/56/a/2"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "6."}, "header": {"#tail": "\n      ", "#text": "Commission\n\t\t\t litigation authority"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "), by striking\n\t\t\t ", "@entity-type": "act", "#text": "subparagraph (D", "@value": "Federal Trade Commission Act/s:16/ss:a/p:2/sp:D"}, "quote": {"#tail": " after the semicolon;", "#text": "or"}, "#text": "in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "id2E28EBA7C1974E82921B96596A8F23A2", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by inserting\n\t\t\t ", "@entity-type": "act", "#text": "subparagraph (E)", "@value": "Federal Trade Commission Act/s:16/ss:a/p:2/sp:E"}, "quote": {"#tail": " after the semicolon; and", "#text": "or"}, "#text": "in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "idB2911E6E4CDE4282B77565BCC589CAB5", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the\n\t\t\t following:", "@entity-type": "act", "#text": "subparagraph (E)", "@value": "Federal Trade Commission Act/s:16/ss:a/p:2/sp:E"}, "#text": "inserting after ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "@id": "id179682837D3F4AB0AB8D35F53125F2E5", "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "subparagraph": {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "act", "#text": "section\n\t\t\t\t28", "@value": "Federal Trade Commission Act/s:28"}, "#text": "under "}, "enum": {"#tail": "\n            ", "#text": "(F)"}, "@id": "id7902E2B4ACBC42E7B3DEF865EE351259", "#text": "\n            "}}, "#text": "\n        ", "@id": "id63D1E5C340104384BC9406B21C20138C"}], "#text": "\n      ", "@id": "idC9F9F7A1B7B843BD9B566BBFDBD03077"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "\n\t\t\t shall commence any enforcement proceeding described in ", "@entity-type": "federal-body", "#text": "Commission", "@entity-id": "2900"}, {"#tail": ", as added by ", "@entity-type": "act", "#text": "section 28 of the\n\t\t\t Federal Trade Commission Act", "@value": "Federal Trade Commission Act/s:28"}, {"#tail": ", except for an action\n\t\t\t described in ", "@entity-type": "act", "#text": "section 3", "@value": "Preserve Access to Affordable Generics Act/s:3", "@proposed": "true"}, {"#tail": ", not later\n\t\t\t than 3 years after the date on which the parties to the agreement file the\n\t\t\t Notice of Agreement as provided by ", "@entity-type": "act", "#text": "section 28(g)(2) of the Federal Trade Commission Act", "@value": "Federal Trade Commission Act/s:28/ss:g/p:2"}], "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "sections 1112(c)(2)", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112/ss:c/p:2"}, {"#tail": " (", "@entity-type": "act", "#text": "(d) of the Medicare\n\t\t\t Prescription Drug Improvement and Modernization Act of 2003", "@value": "Medicare Prescription Drug Improvement and Modernization Act of 2003/s:1112/ss:d/p:2"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 355\n\t\t\t note", "@value": "usc/21/355/note"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "7."}, "header": {"#tail": "\n      ", "#text": "Statute of\n\t\t\t limitations"}, "#text": "\n      ", "@id": "id28AB8E1DB7E5420C9054280D5AC464DF"}, {"#tail": "\n  ", "text": {"#tail": "\n\t\t", "#text": "If any provision of this Act, an amendment\n\t\t\t made by this Act, or the application of such provision or amendment to any\n\t\t\t person or circumstance is held to be unconstitutional, the remainder of this\n\t\t\t Act, the amendments made by this Act, and the application of the provisions of\n\t\t\t such Act or amendments to any person or circumstance shall not be affected\n\t\t\t thereby.", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "8."}, "header": {"#tail": "\n      ", "#text": "Severability"}, "#text": "\n      ", "@id": "idCED49D6C42BC495C8D577636AB338618"}], "#text": "\n\t\t", "@display-enacting-clause": "no-display-enacting-clause"}, "#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "S. 214"}, "official-title": {"#tail": "\n\t", "#text": "To prohibit brand name drug companies from compensating\n\t\t  generic drug companies to delay the entry of a generic drug into the\n\t\t  market."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130204", "#text": "February 4, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "SSJU00", "#text": "Committee on the\n\t\t\t Judiciary"}, "sponsor": {"#tail": " (for\n\t\t\t herself, ", "#text": "Ms. Klobuchar", "@name-id": "S311"}, "cosponsor": [{"#tail": ",\n\t\t\t ", "#text": "Mr. Grassley", "@name-id": "S153"}, {"#tail": ", ", "#text": "Mr. Durbin", "@name-id": "S253"}, {"#tail": ", and ", "#text": "Mr.\n\t\t\t Franken", "@name-id": "S332"}, {"#tail": ") introduced the following bill; which was read twice and\n\t\t\t referred to the ", "#text": "Mr. Johnson of South\n\t\t\t Dakota", "@name-id": "S257"}]}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}}}